Lead drug candidate C21: A novel disease modifier

Vicore Pharma has developed a unique platform technology to treat a wide range of unmet medical needs. The main project is focused on idiopathic pulmonary fibrosis (IPF), a chronic, progressive lung disease for which there is no real effective treatment currently available for patients suffering from the condition.

Subscribe to receive our latest news


Choose what information types you want to subscribe on.


Latest news

Share information

Highlights

Orphan designations for IPF
  • EMA granted.
  • FDA granted.
Phase 1 clinical trial
  • In collaboration with Clinical Research Services Turku.
  • First in man – healthy male volunteers.
  • Primary objectives – safety and tolerability, PK properties.
  • Single and multiple ascending dose studies.
Strong impact on several markers in an in vitro study for pulmonary fibrosis
  • The study showed that C21 was most active in the fibrotic lung disease model where it positively affected several markers indicative of inflammation and fibrosis in a dose dependent manner. C21 exerted stronger effects in the BioMAP® system than the currently approved drugs for IPF.
  • Positive effects on both matrix-related and inflammation-related readouts demonstrated by C21, may translate to a stronger clinical impact than current therapies.
  • C21 was also shown to be active and non-cytotoxic in the BioMAP panel for the concentration range tested.
New drug molecules
  • Developed new drug molecules that selectively stimulate the AT2 receptor (AT2R agonism) in the Renin-Angiotensin-System. Based on experience and learnings drawn from the company’s successful drug candidate, C21, the new molecules have been designed to address diseases in the metabolic and cardiovascular areas.
  • The new molecules open up new opportunities within larger indication areas besides the orphan drug space where C21 is being developed.
  • Patent application filed.

Idiopathic pulmonary fibrosis (IPF)

  • Rare disease with orphan drug status.
  • Unknown cause.
  • Increasing prevalence – 15-20 cases per 100 000 people.
  • Characterized by progressive fibrosis (scar formation) in the lungs, which leads to symptoms increasing over time.

We'd love to hear from you!

Drop us a line and we will respond to you as soon as possible.